Antipituitary Antibodies in Patients with Lymphocytic HypophysitisTakao T. · Nanamiya W. · Matsumoto R. · Asaba K. · Okabayashi T. · Hashimoto K.
Second Department of Internal Medicine, Kochi Medical School, Nankoku, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Lymphocytic hypophysitis is one of the causes of hypopituitarism, which is considered an autoimmune reaction in the anterior pituitary. Method: We examined antipituitary antibodies in patients with lymphocytic hypophysitis and related diseases by immunoblotting method. Results: Autoantibodies to a 22-kDa human pituitary cytosolic protein were identified in significantly higher frequencies in sera from patients with lymphocytic hypophysitis (11 of 15, 73.3%) and isolated ACTH deficiency (7 of 9, 77.8%) compared with Hashimoto thyroiditis, Basedow’s disease and normal control subjects. Also, reactivity against a 49-kDa human pituitary cytosolic protein was seen in 6 of 15 patients (40%) with lymphocytic hypophysitis. N-terminal amino acid sequences of 22-kDa human and rat pituitary cytosolic protein were FPTIPLSVL and FPAMPLSSLFAN, respectively, suggesting that they are human and rat growth hormone, respectively. The pituitary dysfunction (at least one hormone dysfunction) was observed in 11 of 14 patients. Nine of them (82%) showed 22 kDa antibody but 2 of them (18%) did not. Conclusion: The present study demonstrated that pituitary autoantibodies could be involved in the pathogenesis of lymphocytic hypophysitis and could be a positive marker for the disease.
© 2002 S. Karger AG, Basel
Bottazzo GF, Pouplard A, Florin-Christensen A, Doniach D: Autoantibodies to prolactin-secreting cells of human pituitary. Lancet 1975;ii:97–101.
- Hansen BL, Hegedus L, Hansen GN, Hagen C, Hansen JM, Hoier-Madsen M: Pituitary-cell autoantibody diversity in sera from patients with untreated Graves’ disease. Autoimmunity 1989;5:49–87.
- Sugiura M, Hashimoto A, Shizawa M, Tsukada M, Maruyama S, Ishido T, Kasahara T, Hirata Y: Heterogeneity of anterior pituitary cell antibodies detected in insulin-dependent diabetes mellitus and adrenocorticotropic hormone deficiency. Diabetes Res 1986;3:111–114.
Scherbaum WA, Schrell U, Gluck M, Fahlbusch R, Pfeiffer EF: Autoantibodies to pituitary corticotropin-producing cells: Possible marker for unfavorable outcome after pituitary microsurgery for Cushing’s disease. Lancet 1987;i:1394–1398.
- Pouplard A, Bottazo GF, Doniach D, Roitt I: Binding of human immunoglobulins to pituitary ACTH cells. Nature 1976;261:142–144.
- Crock PA: Cytosolic autoantigens in lymphocytic hypophysitis. J Clin Endocrinol Metab 1998;83:609–618.
- Yabe S, Murakami M, Maruyama K, Miwa H: Fukumura Y, Ishii S, Sagiura M, Kobayashi I: Western blot analysis of rat pituitary antigens recognized by human antipituitary antibodies. Endocr J 1995;42:115–119.
- Kikuchi T, Yabe S, Kanda T, Kobayashi I: Antipituitary antibodies as pathogenetic factors in patients with pituitary disorders. Endocr J 2000;47:407–416.
- Komatsu M, Kondo T, Yamauchi K, Yokokawa N, Ichikawa K, Ishihara M, Aizawa T, Yamada T, Imai Y, Tanaka K, Taniguchi K, Watanabe T, Takahashi Y: Antipituitary antibodies in patients with the primary empty sella syndrome. J Clin Endocrinol Metab 1988;67:633–638.
- Stromberg S, Crock P, Lernmark A, Hulting AL: Pituitary autoantibodies in patients with hypopituitarism and their relatives. J Endocrinol 1998;157:475–480.
- Hashimoto K, Takao T, Makino S: Lymphocytic adenohypophysitis and lymphocytic infundibuloneurohypophysitis. Endocr J 1997;44:1–10.
- Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, Fujisawa I, Yamabe H: Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993;329:683–689.
- Nishioka H, Ito H, Sano T, Ito Y: Two cases of lymphocytic hypophysitis presenting with diabetes insipidus: A variant of lymphocytic infundibulo-neurohypophysitis. Surg Neurol 1996;46:285–291.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.